BİLİMSEL PROGRAM
Bilimsel Program en yakın zamanda açıklanacaktır
12.05.2023
13:30 – 13:45
HALL A
OPENING CEREMONY
12.05.2023
13:45 – 14:00
HALL A
BREAK
12.05.2023
14:00 – 15:30
HALL A
INDOLENT LYMPHOMAS
- Follicular Lymphoma — Eva Kimby
- Marginal Zone Lymphoma — Catherine Thieblemont
- Cell-Therapies in Indolent Lymphomas — Koen Van Besien
HALL B
PEDIATRIC LEUKEMIAS-I
- Ped AL Project — Christian M Zwaan
- Pediatric Studies With Inotuzumab Ozagamicin — Edoardo Pennesi
- Studies on Precision Dosing of ATMPs — Caroline Lindemans
12.05.2023
15:30 – 16:00
BREAK
12.05.2023
16:00 – 17:30
HALL A
MYELOPROLIFERATIVE DISORDERS
- Limits and Advances in TFR, Data From National Italian Registry — Carmen Fava
- Digital PCR and Its Future Role in CML — Simona Bernardi
- CML Diagnosed During Pregnancy: How To Manage a Challenging Situation — Ekaterina Chelysheva
HALL B
PEDIATRIC LEUKEMIAS-II
- Pediatric ALL — Mats Heyman
- Pediatric AML — Gertjan J. L. Kaspers
- Pediatric APL — Matthew Kutny
12.05.2023
17:30 – 18:00
BREAK
12.05.2023
18:00 – 19:30
HALL A
MULTIPLE MYELOMA
- Future Management of Smoldering MM — Marivi Mateos
- Future Management of Transplant Eligible NDMM — Amrita Krishnan
- Future Management of Transplant Ineligible NDMM — Saad Usmani
12.05.2023
19:30 – 20:00
HALL A
BREAK
12.05.2023
20:00 – 21:30
HALL A
ACUTE MYELOID LEUKEMIA
- Improving Approaches To Transplant and Post-transplant Approaches in AML — Charles Craddock
- Updates and Developments in The Treatment of Frontline Older/Unfit AML — Tapan Kadia
- Current Status and Novel Combinations With FLT3 Inhibitor Based Therapies
13.05.2023
10:30 – 12:00
HALL A
ACUTE LYMPHOBLASTIC LEUKEMIA
- The European Working Group in Adult ALL — What Do We Do? – Adele Fielding
- New EWALL Guidelines on Management of Adult ALL — Nicola Gökbuget
- Precision Diagnostics and Minimal Residual Disease — Elizabeth Macintyre
- EWALL-TARGET for Precision Therapy
13.05.2023
12:00 – 12:30
BREAK
13.05.2023
12:30 – 13:15
HALL A
ORAL PRESENTATIONS – I
- INFECTION FREQUENCY AND DISTRIBUTION IN CASES USING KINASE INHIBITORS IN HEMATOLOGY: RETROSPECTIVE REAL-LIFE EXPERIENCE — Hülya Yılmaz Tekinhatun
- INFECTIOUS COMPLICATIONS OF PEDIATRIC ALL PATIENTS IN A SINGLE CENTER WITH COMPARISON OF 2 TREATMENT PROTOC
13.05.2023
13:15 – 13:45
BREAK
13.05.2023
13:45 – 15:15
HALL A
AGGRESSIVE LYMPHOMAS
- Diffuse Large B-cell Lymphoma — Can We Beat R-CHOP? – Graham Collins
- Burkitt Lymphoma — Improving Outcomes – Martine Chamuleau
- Primary Mediastinal B-cell Lymphoma — Progress in Frontline and Relapsed Disease – David Sibon
13.05.2023
15:15 – 15:45
BREAK
13.05.2023
15:45 – 16:30
HALL A
ORAL PRESENTATIONS – II
- ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND/OR REFRACTORY HODGKIN LYMPHOMA:A MULTICENTER REAL WORLD EXPERIENCE — Derya Koyun
- THE EFFECT OF INTERLEUKIN-2 GENE POLYMORPHISMS (IL-2 RA, -330 T/G,+166 T/G) ON MULTIPLE MYELOMA — Yasin Çolak
- THE C
13.05.2023
16:30 – 17:00
BREAK
13.05.2023
17:00 – 18:30
HALL A
CHRONIC LYMPHOCYTIC LEUKEMIA
- Covalent versus Non-Covalent BTKi — Implications for Treatment Sequencing – Meghan Thompson
- CLL Targets Beyond BTKi and Bcl2i — Alexey Danilov
- Treatment Landscape of CLL in 2023 — Othman Al – Sawaf
13.05.2023
18:30 – 19:00
BREAK
13.05.2023
19:00 – 20:30
HALL A
HODGKIN LYMPHOMA
- The New Face of Frontline Therapy — Pamela Allen
- Relapsed Disease: Can We Do With Less? — Jane Winter
- Nodular Lymphocyte Predominant Hodgkin Lymphoma, a 2022 Update — Pam Mckay
13.05.2023
20:30 – 20:45
HALL A
CLOSING REMARKS
12.05.2023
13:30 – 13:45
HALL A
OPENING CEREMONY
12.05.2023
13:45 – 14:00
HALL A
BREAK
12.05.2023
14:00 – 15:30
HALL A
INDOLENT LYMPHOMAS
- Follicular Lymphoma — Eva Kimby
- Marginal Zone Lymphoma — Catherine Thieblemont
- Cell-Therapies in Indolent Lymphomas — Koen Van Besien
HALL B
PEDIATRIC LEUKEMIAS-I
- Ped AL Project — Christian M Zwaan
- Pediatric Studies With Inotuzumab Ozagamicin — Edoardo Pennesi
- Studies on Precision Dosing of ATMPs — Caroline Lindemans
12.05.2023
15:30 – 16:00
BREAK
12.05.2023
16:00 – 17:30
HALL A
MYELOPROLIFERATIVE DISORDERS
- Limits and Advances in TFR, Data From National Italian Registry — Carmen Fava
- Digital PCR and Its Future Role in CML — Simona Bernardi
- CML Diagnosed During Pregnancy: How To Manage a Challenging Situation — Ekaterina Chelysheva
HALL B
PEDIATRIC LEUKEMIAS-II
- Pediatric ALL — Mats Heyman
- Pediatric AML — Gertjan J. L. Kaspers
- Pediatric APL — Matthew Kutny
12.05.2023
17:30 – 18:00
BREAK
12.05.2023
18:00 – 19:30
HALL A
MULTIPLE MYELOMA
- Future Management of Smoldering MM — Marivi Mateos
- Future Management of Transplant Eligible NDMM — Amrita Krishnan
- Future Management of Transplant Ineligible NDMM — Saad Usmani
12.05.2023
19:30 – 20:00
HALL A
BREAK
12.05.2023
20:00 – 21:30
HALL A
ACUTE MYELOID LEUKEMIA
- Improving Approaches To Transplant and Post-transplant Approaches in AML — Charles Craddock
- Updates and Developments in The Treatment of Frontline Older/Unfit AML — Tapan Kadia
- Current Status and Novel Combinations With FLT3 Inhibitor Based Therapies
13.05.2023
10:30 – 12:00
HALL A
ACUTE LYMPHOBLASTIC LEUKEMIA
- The European Working Group in Adult ALL — What Do We Do? – Adele Fielding
- New EWALL Guidelines on Management of Adult ALL — Nicola Gökbuget
- Precision Diagnostics and Minimal Residual Disease — Elizabeth Macintyre
- EWALL-TARGET for Precision Therapy
13.05.2023
12:00 – 12:30
BREAK
13.05.2023
12:30 – 13:15
HALL A
ORAL PRESENTATIONS – I
- INFECTION FREQUENCY AND DISTRIBUTION IN CASES USING KINASE INHIBITORS IN HEMATOLOGY: RETROSPECTIVE REAL-LIFE EXPERIENCE — Hülya Yılmaz Tekinhatun
- INFECTIOUS COMPLICATIONS OF PEDIATRIC ALL PATIENTS IN A SINGLE CENTER WITH COMPARISON OF 2 TREATMENT PROTOC
13.05.2023
13:15 – 13:45
BREAK
13.05.2023
13:45 – 15:15
HALL A
AGGRESSIVE LYMPHOMAS
- Diffuse Large B-cell Lymphoma — Can We Beat R-CHOP? – Graham Collins
- Burkitt Lymphoma — Improving Outcomes – Martine Chamuleau
- Primary Mediastinal B-cell Lymphoma — Progress in Frontline and Relapsed Disease – David Sibon
13.05.2023
15:15 – 15:45
BREAK
13.05.2023
15:45 – 16:30
HALL A
ORAL PRESENTATIONS – II
- ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND/OR REFRACTORY HODGKIN LYMPHOMA:A MULTICENTER REAL WORLD EXPERIENCE — Derya Koyun
- THE EFFECT OF INTERLEUKIN-2 GENE POLYMORPHISMS (IL-2 RA, -330 T/G,+166 T/G) ON MULTIPLE MYELOMA — Yasin Çolak
- THE C
13.05.2023
16:30 – 17:00
BREAK
13.05.2023
17:00 – 18:30
HALL A
CHRONIC LYMPHOCYTIC LEUKEMIA
- Covalent versus Non-Covalent BTKi — Implications for Treatment Sequencing – Meghan Thompson
- CLL Targets Beyond BTKi and Bcl2i — Alexey Danilov
- Treatment Landscape of CLL in 2023 — Othman Al – Sawaf
13.05.2023
18:30 – 19:00
BREAK
13.05.2023
19:00 – 20:30
HALL A
HODGKIN LYMPHOMA
- The New Face of Frontline Therapy — Pamela Allen
- Relapsed Disease: Can We Do With Less? — Jane Winter
- Nodular Lymphocyte Predominant Hodgkin Lymphoma, a 2022 Update — Pam Mckay
13.05.2023
20:30 – 20:45
HALL A